West Nile Immune Globulin - OMRIX

Drug Profile

West Nile Immune Globulin - OMRIX

Alternative Names: Omr-IgG-am™-WNIG; WNIG

Latest Information Update: 07 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - West Nile virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued West Nile virus infections

Most Recent Events

  • 07 Sep 2015 Discontinued - Phase-II for West Nile virus infections in USA (IV)
  • 16 Aug 2010 Phase-II clinical trials in West Nile virus infections in USA (IV)
  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top